Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer

Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.

Crosstalk between ER and HER family receptors. ER, estrogen receptor;

Loss of PR reduces the ESR1 expression in hormone-deprived T47D breast

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Schematic diagram of estrogen receptor signaling in breast cancer.

Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018

Updates in endocrine therapy for metastatic breast cancer

ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor

IJMS, Free Full-Text

image.slidesharecdn.com/hormonetherapyinbreastcanc

Cancers, Free Full-Text